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utilization, lower QoL and greater work impairment. Additional research is war-
ranted to further characterize the impact of cost and reimbursement on patient
outcomes.
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OBJECTIVES: Limited data exist on the economic impact of SLE flares. This study
estimatedHRUand costs of SLE flares in aU.S.Medicaid population.METHODS: SLE
Patients 18 years old were extracted from a large Medicaid database 2002-2009.
Index date was the date of the first SLE diagnosis. All patients were continuously
enrolled for6months before and12months after index date and followed until
the earliest of inpatient death, end of enrollment, or end of study. Mild, moderate,
and severe flareswere identified in the follow-up period. Costs attributable to flares
weremeasured during 30 days following a flare. If a flare of higher severity occurred
within 30 days, the length was limited to the period up to the start of the new flare.
RESULTS: 14,262 patients met the study criteria and 97% experienced at least one
flare during an average follow-up of 39 months (3,540 had severe, 9,597 had mod-
erate, and 669 hadmild flares as theirmost severe flares). Mean costs per flarewere
$11,716, $562 and $129 for severe, moderate, and mild flares, respectively. Patients
with 1 severe flares during follow-up had 1.7 inpatient (IP) admissions, 3.5 emer-
gency room (ER) visits, and 16.0 outpatient (OP) visits with a total medical cost of
$49,754per year. Patients with 1 moderate flares but no severe flares had 0.9 IP
admissions, 2.4 ER visits, and 12.8 OP visitswith a cost of $21,941. Patientswith only
mild flares had the least HRU of 1.0 IP admission, 1.5 ER visits, and 7.5 OP visits with
a cost of $17,574. Patients with severe andmoderate but nomild flares and patients
with severe flares only incurred the highest annual cost ($66,412 and $74,491,
respectively). CONCLUSIONS: Flares occurred in almost all SLE patients and were
associated with a significant economic burden.
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OBJECTIVES: Immune tolerance induction (ITI) is generally accepted as first choice
treatment to eradicate inhibitors in hemophilia A patients. Little is known about
the outcomes and cost consequences of this treatment option. METHODS: The
Immune Tolerance and Economics Retrospective (ITER) study is an observational,
retrospective, multicentre, multinational study aiming to estimate cost of treat-
ment in hemophilia A patients, undergoing ITI. Data on hemostatic treatment
given in the following time periods were collected: up to 12 months before the
diagnosis of Inhibitors, between Inhibitors diagnosis and ITI start, during ITI, and
12 months after the end of ITI. Costs of treatment were calculated in the perspec-
tive of the third party payer and expressed as mean €/patient-month. RESULTS:
Seventy-one valid patients, with median age at ITI start3.8 (0.4-41) years, were
enrolled. Before ITI the median Inhibitors peak titre was 18.5 (0.80-704) BU. ITI was
applied for a mean of 1.85 (0.1-14.0) years and was successful in 84.5% pts. Before
Inhibitors diagnosis, patients cost was 670.2 €/patient-month. Cost was 3,188€/
patient-month between the Inhibitors diagnosis and ITI start (92.1% for bypassing
agents), and 60,078€ during ITI (76.8% for ITI, 19.4% for extra FVIII treatment, 3.8%
for extra treatment with bypassing agents). The mean cost after ITI was
13,211€/patient-month. CONCLUSIONS: ITI applied on patients with the character-
istics of those involved in the ITER study is successful in 84% of themat amean cost
of 60,000€/patient-month during ITI, plus 13,000€/patient-month through 1 year
later. Further research is encouraged to value long term benefits and costs attrib-
utable to ITI versus other treatment options, in order to identify the most efficient
treatment for the patients and for the health care system.
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OBJECTIVES: Limited information is available on the cost effectiveness of newer
biologic agents for treatment of psoriasis. The objective of this study is, from a
United States societal perspective, to compare the cost-effectiveness of etanercept
and ustekinumab therapy in patients with moderate-to-severe psoriasis based on
head-to-head clinical trial information. METHODS: A Markov model was con-
structed to simulate the incremental cost per quality-adjusted life year gained.
Costs were estimated from the societal perspective in the United States over a time
horizon of five years. All cost and effectiveness estimates were obtained from the
relevant literature. An annual discount rate of 3%was applied to costs and quality-
adjusted life years. All costs were adjusted to 2011 US dollars. One-way and thresh-
old sensitivity analyses assessed the robustness of model results. RESULTS: In the
base case, over a 5-year time horizon, ustekinumab 45 mg was dominant versus
etanercept 50 mg. The base case incremental cost-effectiveness ratio (ICER) com-
paring ustekinumab 90 mg with etanercept 50 mg averaged $267,761 per QALY
gained. The ICER comparing ustekinumab 90mgwith ustekinumab 45mgaveraged
$915,179 per QALY gained. ICERs were quite sensitive to unit prices for usteki-
numab and etanercept. CONCLUSIONS: Given the limitations of the available data,
ustekinumab 45 mg was dominant over etanercept 50 mg for a five-year time
horizon, whereas ustekinumab 90 mg was more costly and marginally more effec-
tive than etanercerpt 50 mg. Ustekinumab 90 mg would not be considered cost
effective using a US willingness-to-pay threshold of $120,000-150,000 per QALY.
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OBJECTIVES: Patients with chronic pain due to osteoarthritis (OA) or rheumatoid
arthritis (RA) do not often obtain adequate relief or experience unacceptable side
effects due their pain-control treatments. The objective of this study was to per-
form a cost-effectiveness analysis comparing celecoxib, etoricoxib and lumira-
coxib in the treatment of chronic pain in patients with OA and RA, from the Mex-
ican Social Security Institute (IMSS) perspective.METHODS: A decision-tree model
(12-weeks time horizon) was used to compare pain reduction and direct medical
costs associated to competing alternatives. A systematic literature reviewwas per-
formed to identify the pain reduction (reported through visual analogue scales) and
adverse events (AE) incidence rate associated. Comparatorswere: celecoxib 200mg/
day, etoricoxib 90mg/day and lumiracoxib 100mg/day for patients with OA and RA.
A meta-analysis with selected publications (n10) was performed. Resource utili-
zationwas extracted from clinical practice guidelines and unit costswere retrieved
from IMSS official sources. Probabilistic sensitivity analysis was performed. Ac-
ceptability curves were developed. RESULTS: Pain reductions vs. placebo were:
celecoxib 14.18% (CI95% 10.48-17.87, p0.00001); etoricoxib 12.70% (7.67-17.73,
p0.00001) and lumiracoxib 9.47% (7.17-11.77, p0.00001). Differences between
celecoxib and lumiracoxib was meaningful (p0.05). The odds ratios of AE inci-
dence vs. placebo were: 1.06 (0.77-1.46, p0.37); 1.09 (0.87-1.36, p0.73) and 1.44
(0.88-2.34, p0.14), respectively. The expected medical costs (2011 US$) were:
$197.93 ($9.52); $221.54 ($7.06) and $306.65 ($12.86), respectively. The cost of
management of AE contributed with $101.28, $95.00 and $146.17 of the overall
expected costs, respectively. In regards to etoricoxib (basecase), celecoxib showed
to be a cost-saving strategy with a cost-effective proportion of 76.7% (74.1%-79.3%);
while lumiracoxib was the less effective and more costly strategy. CONCLUSIONS:
At IMSS, celecoxib patients who suffer OA or RA would reach a higher incremental
reduction in pain intensity at 12 weeks reducing overall costs in comparison to
etoricoxib.
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OBJECTIVES: In the French setting, uncontrolled bleeding episodes in hemophilia
patients with inhibitors require emergency/inpatient care. The impact of on-de-
mand (OD) treatment of bleeding episodes remain rarely quantified in France.
METHODS:Wemodeled the lifetime number of bleeding episodes and hospitaliza-
tions associated with recombinant activated Factor VIIa (rFVIIa) and plasma-de-
rived activated prothrombin complex concentrate (pd-aPCC) to investigate the im-
pact of faster bleeding resolution of a new bypassing agent (BA) by applying
hypothetical adjustments to the performance of rFVIIa. The exploratory semi-
Markov model assumed a French payer perspective and simulated treatment of
2-year oldmale hemophilia patientswith high-responding inhibitors.Model inputs
were obtained from published international studies and French government
sources. Comparisons of the current BAs pertaining to dosing and base-case effi-
cacy rates were obtained from a Bayesian meta-analysis pooling available esti-
mates. Model outcomes included the rate of hospitalization due to uncontrolled
bleeds and number of minor/major bleed over lifetime. Sensitivity analyses were
performed to test robustness of the model. RESULTS: rFVIIa required 4% fewer
hospitalizations for bleed treatment than pd-aPCC, as well as a reduction in life-
time bleeds. rFVIIa resulted in 667 minor bleeds over the patient’s lifetime com-
pared with 673 in patients treated with pd-aPCC. When adopting potential im-
provements for a hypothetical new BA, faster bleed resolution that results in fewer
rebleeds reduces hospitalizations by 13% in the rFVIIa arm compared to base case.
CONCLUSIONS: Additional research is needed to understand how increased bleed
control and faster resolution of bleeds in French inhibitor patients translate into a
reduction in other health resources utilization such as emergency visits to hemo-
philia treatment centers and indirect costs including missed school/productivity
loss which can improve the quality of life of patients and caregivers.
PSY30
COST UTILITY ANALYSIS OF THE PROFILAXIS VERSUS ON-DEMAND
TREATMENT WITH RECOMBINANT FACTOR IX FOR THE TREATMENT OF
HEMOPHILIA B IN MEXICO
Muciño-Ortega E1, Leyva-Bravo V2, Gutiérrez C1, Galindo-Suárez RM1
1Pfizer S.A. de C.V., Mexico City, Mexico, 2IMS Heatlh México, Ciudad de México, Mexico
A103V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
